Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma.
Wiedemeyer K, Wang L, Kang EY, Liu S, Ou Y, Kelemen LE, Feil L, Anglesio MS, Glaze S, Ghatage P, Nelson GS, Köbel M.
Int J Gynecol Pathol. 2022 Mar 1;41(2):168-179. doi: 10.1097/PGP.0000000000000780.
"Early" Clear Cell Proliferations (Clear Cell Carcinoma in Situ) in Ovarian Endometriotic Cysts: Report of a Case Series With Recommendations for Terminology.
Karunadhas NS, Catherwood M, Stringfellow H, Arora R, McCluggage WG.
Am J Surg Pathol. 2025 May 6;49(9):901-908. doi: 10.1097/PAS.0000000000002415.
'STIC-like' lesions in ovarian low-grade serous carcinoma: a diagnostic pitfall.
Machuca-Aguado J, McCluggage WG.
Histopathology. 2023 Sep;83(3):489-492. doi: 10.1111/his.14967. Epub 2023 Jun 25.
Novel LAMC2 fusion protein has tumor-promoting properties in ovarian carcinoma.
Daisuke H, Kato H, Fukumura K, Mayeda A, Miyagi Y, Seiki M, Koshikawa N.
Cancer Sci. 2021 Dec;112(12):4957-4967. doi: 10.1111/cas.15149. Epub 2021 Nov 5.
Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma.
Gorczyński A, Miszewski K, Gager Y, Koch S, Pötschke J, Ugrinovski D, Gabert J, Pospieszyńska A, Wydra D, Duchnowska R, Szymanowski B, Cierniak S, Kruecken I, Neumann K, Mirkov K, Biernat W, Czapiewski P.
Cancer Biomark. 2023;38(1):17-26. doi: 10.3233/CBM-230117.
Amplification of 11q13 in ovarian carcinoma.
Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG.
Genes Chromosomes Cancer. 2008 Jun;47(6):481-9. doi: 10.1002/gcc.20549.
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.
Jiang RT, Yemelyanova A, Xing D, Anchoori RK, Hamazaki J, Murata S, Seidman JD, Wang TL, Roden RBS.
J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.
Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Tropé CG, van de Putte G, Reich R.
Am J Clin Pathol. 2002 Feb;117(2):225-34. doi: 10.1309/u40r-1bn4-6kj3-bdg3.
Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma.
Bui CM, Oren A, Balzer B, Maluf H, Medeiros F.
Appl Immunohistochem Mol Morphol. 2024 May-Jun 01;32(5):222-228. doi: 10.1097/PAI.0000000000001194. Epub 2024 Apr 18.
Fluorescence in situ hybridization analysis using cosmid probes to define chromosome 6q abnormalities in ovarian carcinoma cell lines.
Lastowska MA, Lillington DM, Shelling AN, Cooke I, Gibbons B, Young BD, Ganesan TS.
Cancer Genet Cytogenet. 1994 Oct 15;77(2):99-105. doi: 10.1016/0165-4608(94)90222-4.
